Advertisement

Will Dolutegravir Instantly Become the Integrase Inhibitor of Choice in Patients with Treatment Failure?

July 15, 2013

Will Dolutegravir Instantly Become the Integrase Inhibitor of Choice in Patients with Treatment Failure?

Yes, barring unexpected toxicity, predicts Dr. Paul Sax in HIV and ID Observations .

In a recent randomized, double-blind trial involving treatment-experienced patients at 156 sites, virologic outcomes were better with dolutegravir than with raltegravir. In addition, dolutegravir is taken only once daily (vs. twice with raltegravir), seems just as well tolerated, has a similar drug–drug interaction profile, and is probably less prone to resistance. In HIV and ID Observations, Dr. Paul Sax predicts that, barring unexpected toxicity when the drug gets into broader use after approval, dolutegravir will quickly become the integrase inhibitor of choice in patients with treatment failure.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement